Install
- 15,146articles · 30d
- 4+ hour agolatest article
- Aug 15, 2026earliest in window
- 94%with images · 8 videos
- 143avg words
- Economy, Business & Finance 14,327
- Finance & Business 13,780
- News 8,290
- Finance 3,878
- Business & Industrial 1,668
- Industrial 455
- Health & Wellness 260
- Politics 191
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
TABLE-Umenohana Group -Q1 group results
16+ hour, 12+ min ago (11+ words) TradingView TABLE-Umenohana Group -Q1 group results...
Price to earnings ratio of Bci Asset Man Adm Cuota De Fondo De Inversion – BCS:CFI_BLMVAE0 – TradingView
23+ hour, 18+ min ago (41+ words) Price to earnings ratio of Bci Asset Man Adm Cuota De Fondo De Inversion – BCS:CFI_BLMVAE0 TradingView Bci Asset Man Adm Cuota De Fondo De Inversion Price to earnings ratio of Bci Asset Man Adm Cuota De Fondo De Inversion...
TNXP: Strong sales growth, pipeline progress, and robust cash position drive optimism for future milestones
3+ day, 23+ hour ago (79+ words) tradingview.com TONMYA's launch for fibromyalgia has shown strong early sales growth and broadening access, with a unique mechanism and favorable tolerability. The pipeline includes a phase II-ready Lyme disease antibody and an anti-CD40 ligand program for transplantation, supported by…...
VRTX: Diversified portfolio advances with key launches and milestones in renal, pain, and endocrinology
3+ day, 23+ hour ago (83+ words) TradingView Recent acquisitions and pipeline progress have diversified the portfolio across five disease pillars, with key milestones ahead in renal, pain, and rare endocrine diseases. Commercial infrastructure has matured, supporting strong product launches and steady growth, especially in pain and…...
IDYA: NDA submission and pivotal data updates set the stage for a major U.S. launch and pipeline growth
4+ day, 43+ min ago (93+ words) TradingView IDYA: NDA submission and pivotal data updates set the stage for a major U.S. launch and pipeline growth Darovasertib is nearing NDA completion with a U.S. launch expected in H1 next year, supported by expedited FDA review and evolving toward an HLA-agnostic…...
ARVN: Four clinical programs near key data milestones, with strong cash runway and robust pipeline strategy
4+ day, 1+ hour ago (87+ words) TradingView ARVN: Four clinical programs near key data milestones, with strong cash runway and robust pipeline strategy The company is advancing four clinical programs with imminent data readouts, supported by a strong cash position and a focus on wholly owned…...
ANIP: Rare disease assets and strategic expansion fuel multi-year growth and strong financial outlook
4+ day, 1+ hour ago (78+ words) TradingView ANIP: Rare disease assets and strategic expansion fuel multi-year growth and strong financial outlook The company is rapidly transforming into a rare disease leader, driven by strong growth in Cortrophin and ILUVIEN, robust generics performance, and strategic expansions into…...
INCY: Late-stage pipeline and focused R&D set the stage for strong growth beyond 2029 — TradingView News
4+ day, 4+ hour ago (77+ words) INCY: Late-stage pipeline and focused R&D set the stage for strong growth beyond 2029 tradingview.com Pipeline assets have advanced to late-stage trials, with five key programs expected to drive post-2029 growth. Strategic R&D investment and selective business development…...
OPK: Transitioning to a therapeutics-focused model with innovative multi-specific assets and strong partnerships
4+ day, 5+ hour ago (76+ words) TradingView OPK: Transitioning to a therapeutics-focused model with innovative multi-specific assets and strong partnerships The company is shifting from diagnostics to therapeutics, highlighted by ModeX's unique multi-specific antibody platform and a robust pipeline in oncology, immunology, and infectious diseases. Strategic…...
OPK: Transitioning to a therapeutics-focused model with unique multi-specific assets and strong partnerships
4+ day, 5+ hour ago (76+ words) TradingView OPK: Transitioning to a therapeutics-focused model with unique multi-specific assets and strong partnerships The company is shifting from diagnostics to therapeutics, highlighted by ModeX’s multi-specific antibody platform and a robust clinical pipeline. Strategic collaborations with Merck and Regeneron, strong…...